NRX-101

Small molecule

NNeuroRx, Inc.

NRX-101 is one of 58 small molecule programs targeting Suicidal Ideation. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Suicidal IdeationActive, not recruiting

Treatment Resistant DepressionActive, not recruiting

Suicidal IdeationPhase 2/Phase 3

Active, not recruiting

Treatment Resistant DepressionPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

62 competitors in Treatment Resistant Depression

#DrugCompanyPhaseTrials

Ketalar

AAultman Health Foundation

Approved

22 2

Spravato

WWim Janssens

Approved

16 3

Risperdal

WWim Janssens

Approved

5 4

Bayer Aspirin

Bayer

Approved

—5

Lithobid

SSolvay Pharmaceuticals

Approved

4 6

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Approved

3 7

Abilify

Otsuka

Approved

3 8

Wellbutrin

GGlaxo Dba Glaxosmithkline

Approved

2 9

Lithobid

SSolvay Pharmaceuticals

Approved

—10

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

PreclinicalNot yet recruiting

Treatment Resistant Depression

NCT07227103

Clinical

Trials by Indication[1]

Bipolar Depression2 trials

Sequential Therapy for the Treatment of Severe Bipolar Depression.

Completed·NNeuroRx, Inc.·Phase 2·NCT02974010·22 enrolled

NRX-101 for Treatment-Resistant Bipolar Depression in Patients At Risk for Self-Harm

No longer available·NNeuroRx, Inc.··NCT05779267

Suicidal Ideation2 trials

NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation

Unknown status·NNeuroRx, Inc.·Phase 3·NCT03396068·72 enrolled

NRX-101 for Bipolar Depression With Subacute Suicidal Ideation

Completed·NNeuroRx, Inc.·Phase 2/3·NCT03395392·74 enrolled

Biomarker1 trial

NRX101 Glx Biomarker Validation Study

Completed·NNeuroRx, Inc.·Phase 2/3·NCT03402152·8 enrolled

Treatment Resistant Depression1 trial

A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial

Not yet recruiting·NNeuroRx, Inc.·Preclinical·NCT07227103·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for NRX-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NRX-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NRX-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NeuroRx, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: NNeuroRx, Inc.

NRX-101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Bipolar Depression2 trials

Suicidal Ideation2 trials

Biomarker1 trial

Treatment Resistant Depression1 trial

References

Drug Info

Quick Facts

Related News